🇺🇸 FDA

Company profile · Sponsor

Coherus

Coherus Oncology

CHRS · NYSE biotech REDWOOD CITY, CA, USA
Pipeline
24
Drugs
3
Patents
8

Quick answer

Coherus (CHRS) is a biotech company. headquartered in REDWOOD CITY, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 8 patents to this profile..

Company facts

Ticker CHRS
Exchange NYSE
Company type biotech
Headquarters REDWOOD CITY, CA, USA
SEC CIK 0001512762

Pipeline (24)

Search pipeline →

  1. CHS-0214

    Coherus

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  2. CHS-1420

    Coherus

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  3. Etanercept

    Coherus

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  4. Etanercept

    Coherus

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  5. Casdozokitug

    Coherus

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  6. Dupilumab

    Coherus

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  7. NY-ESO-1 Peptide vaccine

    Coherus

    Ovarian Cancer Stage IV

    phase 2 mab active

    1 trial

  8. Nadunolimab

    Coherus

    Metastatic Microsatellite Stable Colorectal Carcinoma

    phase 2 small molecule active

    1 trial

  9. SRF388

    Coherus

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  10. STC-15 in combination with toripalimab

    Coherus

    Solid Tumor

    phase 2 other active

    1 trial

  11. Toripalimab

    Coherus

    Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

    phase 2 small molecule active

    1 trial

  12. Toripalimab

    Coherus

    Localized Colon Carcinoma

    phase 2 small molecule active

    1 trial

  13. Toripalimab

    Coherus

    Sinonasal Cancer

    phase 2 small molecule active

    1 trial

  14. Toripalimab + Chemotherapy

    Coherus

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial

  15. Toripalimab-tpzi

    Coherus

    Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  16. CHS-006 (anti-TIGIT)

    Coherus

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  17. CHS-1000

    Coherus

    Advanced or Metastatic Solid Tumors

    phase 1 mab active

    1 trial

  18. CHS-114

    Coherus

    Metastatic Solid Tumor

    phase 1 small molecule active

    1 trial

  19. CHS-114

    Coherus

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  20. CHS-1701

    Coherus

    Immunity, Humoral

    phase 1 small molecule completed

    1 trial

  21. CHS-1701

    Coherus

    Healthy

    phase 1 small molecule completed

    1 trial

  22. CHS-1701

    Coherus

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  23. CHS-388

    Coherus

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  24. SRF617

    Coherus

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

Drugs (3)

Search drugs →

  1. adalimumab-aqvh

    YUSIMRY

    INJECTION approved

  2. pegfilgrastim-cbqv

    UDENYCA

    INJECTION approved

  3. toripalimab-tpzi

    LOQTORZI

    INJECTION approved

Patents (8)

Search patents →

  1. US 11667702

    Stable aqueous formulations of aflibercept

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11583584

    Stable protein compositions and methods of their use

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11576971

    Method of filling a container with no headspace

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11426446

    Stable aqueous formulations of aflibercept

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11400072

    Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11396540

    Methods for making recombinant proteins

    Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11253508

    PPARy agonist for treatment of progressive supranuclear palsy

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11229702

    High concentration formulations of adalimumab

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Coherus?

Coherus (CHRS) is a biotech company. headquartered in REDWOOD CITY, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 8 patents to this profile..

What pipeline programs does Coherus sponsor?

We track 24 ClinicalTrials.gov-linked programs for Coherus, including CHS-0214 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Coherus company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.